Literature DB >> 1671010

Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation.

P Gionchetti1, C Guarnieri, M Campieri, A Belluzzi, C Brignola, P Iannone, M Miglioli, L Barbara.   

Abstract

The in vitro antioxidant capacity of sulfasalazine (SASP), its metabolites (SP, 5-ASA), and olsalazine (OAZ), was studied by evaluating their effects on superoxide (O2-.) production. Assay systems were the xanthine-xanthine oxidase (X/XOD) reaction and phorbol myristate acetate (PMA)-activated polymorphonuclear leukocytes (PMNs), using the cytochrome c (cyt-c) reduction assay and a luminol-dependent chemiluminescence method. 5-ASA, SASP, and OAZ showed a dose-dependent scavenger effect in both O2-. generating systems, 5-ASA being the most powerful (greater than 50% of inhibition in the PMNs system and greater than 70% in the X/XOD system at 10 microM concentration). SP had an inhibitory effect only in the PMNs system but did not modify the activity of xanthine oxidase, thus excluding a scavenger action. These data suggest that the scavenger effect of 5-ASA, SASP, and OAZ may be an important mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671010     DOI: 10.1007/bf01300752

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  In vitro studies on the significance of arachidonate metabolism and other oxidative processes in the inflammatory response of human neutrophils and macrophages. With special reference to chronic inflammatory bowel disease.

Authors:  O H Nielsen
Journal:  Scand J Gastroenterol Suppl       Date:  1988

2.  Distribution studies of salicylazosulfapyridine and its metabolites.

Authors:  M A Peppercorn; P Goldman
Journal:  Gastroenterology       Date:  1973-02       Impact factor: 22.682

3.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.

Authors:  U Klotz; K Maier; C Fischer; K Heinkel
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

4.  Arachidonic acid-induced chemiluminescence of human polymorphonuclear leukocytes.

Authors:  S Yoshimoto; T Yoshimoto; E Tsubura
Journal:  Biochem Biophys Res Commun       Date:  1982-08       Impact factor: 3.575

5.  5-Aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage.

Authors:  B J Dull; K Salata; A Van Langenhove; P Goldman
Journal:  Biochem Pharmacol       Date:  1987-08-01       Impact factor: 5.858

6.  Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils.

Authors:  W F Stenson; E Lobos
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

7.  Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species.

Authors:  Y Miyachi; A Yoshioka; S Imamura; Y Niwa
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

8.  Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.

Authors:  O H Nielsen; K Bukhave; J Elmgreen; I Ahnfelt-Rønne
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199

9.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

10.  Stimulation by oxygen radicals of prostaglandin production by rat renal glomeruli.

Authors:  L Baud; M P Nivez; D Chansel; R Ardaillou
Journal:  Kidney Int       Date:  1981-09       Impact factor: 10.612

View more
  17 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

2.  Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease.

Authors:  A Keshavarzian; A Banan; A Farhadi; S Komanduri; E Mutlu; Y Zhang; J Z Fields
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

3.  5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects.

Authors:  Brian J Day; Jie Huang; Briana Q Barkes; May Gillespie; Li Li; Lisa A Maier
Journal:  Lung       Date:  2017-10-27       Impact factor: 2.584

Review 4.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

5.  Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.

Authors:  C Wahl; S Liptay; G Adler; R M Schmid
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

6.  Effects of zafirlukast on the function of humanpolymorphonuclear neutrophil leukocytes in asthmatic patients: A prospective, controlled, in vitro study.

Authors:  Hana A Al-Zamil; Ali S Ai-Twaijiri; Abdulla F Al-Mobeireek; Ali A Mustafa
Journal:  Curr Ther Res Clin Exp       Date:  2005-07

7.  Nuclear factor-kappa B activation in human testicular apoptosis.

Authors:  Virve Pentikäinen; Laura Suomalainen; Krista Erkkilä; Eeva Martelin; Martti Parvinen; Markku O Pentikäinen; Leo Dunkel
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

8.  Effect of allopurinol, sulphasalazine, and vitamin C on aspirin induced gastroduodenal injury in human volunteers.

Authors:  M E McAlindon; A F Muller; B Filipowicz; C J Hawkey
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

Review 9.  Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

Authors:  Nielsen Q Fernandez-Becker; Alan C Moss
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils.

Authors:  H Allgayer; S Rang; U Klotz; P Böhne; J Retey; W Kruis; R Gugler
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.